Expand Our Knowledge of PRKAG2
Contribute to PRKAG2 Cardiomyopathy Research in 5 Minutes
Contribute to PRKAG2 Cardiomyopathy Research in 5 Minutes
Whether PRKAG2 Syndrome runs in your family or you are the first to be diagnosed, treatment options can be limited.
That’s why we are excited to partner with Atrium Therapeutics (an independent spin-off from Avidity Biosciences). Atrium is advancing a novel investigational therapy using siRNA technology to specifically target the underlying cause of PRKAG2 Syndrome.
You can contribute to this research by signing up for Citizen Health, a secure digital platform that is collaborating with Atrium on a digital natural history study of PRKAG2 Syndrome. A digital natural history study collects real-world, patient-reported data over time using online tools to better understand how a condition develops and affects daily life.
In Just 5 Minutes, You Can Help Shape the Future of PRKAG2 Heart Disease Therapies
If you choose to join the study, Citizen Health will securely and confidentially collect your medical records on your behalf, organize them in one place, and put them under your control to use and share.
- Sign up in about 5 minutes – Citizen Health securely and confidentially collects & organizes your medical records into one profile you control—ready when you or your care team need it most
- Contribute anonymized data to Atrium's study of PRKAG2 Cardiomyopathy, potentially improving the understanding of this ultra-rare disease and that may impact future clinical trial design
- Be contacted about clinical trials – Signing up can keep you informed about future research opportunities, including Atrium's investigational clinical trials
- You maintain complete control over your data-sharing preferences
Your Privacy and Security is Our Priority
We understand the sensitivity of your health information.
That's why we've built our platform with privacy and security at its core:
All data is encrypted both locally and in transit
We use HIPAA-compliant cloud services through Amazon Web Services (AWS)
You maintain complete control over your data-sharing preferences
Our systems undergo regular security audits and compliance reviews
Meet the experts leading data security and privacy
at Citizen and for the Industry
Deven McGraw
Chief Regulatory & Privacy Officer
Daniel Wang
Chief Technology Officer
About The PRKAG2 Collaboration
About PRKAG2 Cardiomyopathy (AKA PRKAG2 Syndrome)
PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Syndrome is an autosomal dominant, progressive cardiac disease caused by a mutation on the PRKAG2 gene that results in increased AMP-activated protein kinase (AMPK) activity. This causes excessive cardiac glycogen storage in the heart, leading to cardiac hypertrophy (thickening of heart muscle) and multiple different types of arrhythmias (irregular heartbeats), including Wolff-Parkinson-White syndrome, atrial fibrillation, and cardiac conduction system disease. As a result, patients with PRKAG2 syndrome are at an increased risk of experiencing sudden cardiac arrest or heart failure. There are no FDA-approved disease-modifying therapies for PRKAG2 Syndrome, and current standard of care focuses on symptom management with medications or invasive treatments including pacemakers or implantable cardioverter defibrillator (ICD). Patients who develop progressive heart failure may require a heart transplant.
About Atrium Therapeutics
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The company’s proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics’ platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from delivery to the skeletal muscle and applies it for efficient delivery to the heart overcoming challenges associated with non-specific tissue delivery. The company’s pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 Cardiomyopathy and ATR 1086 for PLN Cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The company’s proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics’ platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from delivery to the skeletal muscle and applies it for efficient delivery to the heart overcoming challenges associated with non-specific tissue delivery. The company’s pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 Cardiomyopathy and ATR 1086 for PLN Cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/
About Citizen Health
Citizen Health is a consumer health platform dedicated to leveraging technology and real-world data to enhance patient outcomes and streamline drug development. By securely providing patients access to medical records and supportive tools to address daily health challenges, Citizen Health fosters active patient engagement, benefiting both individuals and therapeutic innovation.
About Digital Natural History Studies A digital natural history study is a type of natural history study that uses data already collected in electronic medical records to observe how a disease progresses over time — without intervening or treating differently. A natural history study is a type of research that follows people over time who have a specific disease or condition, without trying to treat or change the course of the condition. The goal is to understand how the disease develops and progresses naturally — hence the name "natural history."
Key features of a natural history study: Observational: No experimental treatment is given — researchers just observe what happens.Longitudinal: It usually tracks participants over a long period to capture how symptoms change or evolve.
Detailed Data Collection: Includes information like genetics, biomarkers, symptoms, imaging, etc.
Helps Identify Patterns: Can reveal different stages of a disease, risk factors, or how it affects various people.
Why are natural history studies important? They provide a baseline for how a disease normally progresses. They help design better clinical trials by identifying the best time to intervene and what outcomes to measure. Especially valuable for rare diseases, where little is known and treatment options are limited.
International Patient Support
We welcome international patients to join Citizen! While we can't collect records for you outside of the US, you can upload your own health data to contribute to research and make a difference today. For support or questions, contact our team at support@citizen.health
